Management of Community-Acquired Pneumonia

Bartlett JG, Breiman RF, Mandell LA, et al. Community-acquired pneumonia in adults: guidelines for management. Clin Infect Dis 1998; 26: 811–38 Marston BJ, Plouffe JE, File TM, et al. Incidence of community-acquired pneumonia requiring hospitalization: results of a population-based active surveillance study in Ohio. Arch Intern Med 1997; 157: 1709–18 Halm E, Switzer G, Mittman B, et al. What factors influence physicians’ decisions to switch from intravenous to oral antibiotics for community-acquired pneumonia?. J Gen Intern Med 2001; 16(9): 599–605 Lave JR, Lin CC, Hughes-Cromick P. The cost of treating patients with community-acquired pneumonia. Semin Respir Crit Care Med 1999; 20: 189–97 McCormick D, Fine MJ, Coley CM, et al. Variation in length of hospital stay in patients with community-acquired pneumonia: are shorter stays associated with worse medical outcomes? Am J Med 1999; 107: 5–12 Lim AF, Tan JS, Murphy DM. Factors influencing length of stay, time to resolution of morbidity, and cost of patient care: a comparative retrospective study of short-stay and long-stay patients hospitalized for simple pneumonia (DRG 89 and 90). Infect Dis Clin Pract 2001; 10: 375–83 Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336: 243–50 Bartlett JG, Dowell SF, Mandell LA, et al. Practice guidelines for the management of community-acquired pneumonia in adults. Clin Infect Dis 2000; 31: 347–82 Atlas SJ, Benzer TI, Borowsky LH, et al. Safely increasing the proportion of patients with community-acquired pneumonia treated as outpatients: an interventional trial. Arch Intern Med 1998; 158: 1350–6 Marrie TJ, Lau CY, Wheeler SL, et al. A controlled trial of a critical pathway for treatment of community-acquired pneumonia. JAMA 2000; 283: 749–55 Halm EA, Fine MJ, Marrie TJ, et al. Time to clinical stability in patients hospitalized with community-acquired pneumonia: implications for practice guidelines. JAMA 1998; 279(18): 1452–7 Ewig S, Schafer H, Torres A. Severity assessment in community-acquired pneumonia. Eur Respir J 2000; 16(6): 1193–201 Dean N, Suchyta M, Bateman K, et al. Implementation of admission decision support for community-acquired pneumonia. Chest 2000; 117(5): 1368–77 Fantin B, Aubert J, Unger P, et al. Clinical evaluation of the management of community-acquired pneumonia by general practitioners in France. Chest 2001; 120(1): 185–92 Fine MJ, Hough LJ, Medsger AR, et al. The hospital admission decision for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research Team cohort study. Arch Intern Med 1997; 157: 36–44 Mandell LA, Marrie TJ, Grossman RF, et al. Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. Clin Infect Dis 2000; 31: 383–421 Macfarlane J, Boswell T, Douglas G, et al. BTS Guidelines for the management of community acquired pneumonia in adults. Thorax 2001; 56Suppl. IV: iv1–iv56 Niederman M. Guidelines for the management of community-acquired pneumonia: current recommendations and antibiotic selection issues. Med Clin North Am 2001; 85(6): 1493–509 Coley CM, Li Y-H, Medsger AR, et al. Preferences for home vs hospital care among low-risk patients with community-acquired pneumonia. Arch Intern Med 1996; 156: 1565–71 Grasela TH, Welage LS, Walawander CA, et al. A nationwide survey of antibiotic prescribing patterns and clinical outcomes in patients with bacterial pneumonia. DICP 1990; 24: 1220–5 Ramirez J. Switch therapy in community-acquired pneumonia. Diagn Microbiol Infect Dis 1995; 22(1–2): 219–23 Niederman MS, Bass Jr JB, Campbell GD, et al. Guidelines for the initial management of adults with community acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. Am Rev Respir Dis 1993; 148: 1418–26 Meehan TP, Fine MJ, Krumholz HM, et al. Quality of care, process, and outcomes in elderly patients with pneumonia. JAMA 1997; 278(23): 2080–4 Battleman DS, Callahan M, Thaler HT. Rapid antibiotic delivery and appropriate antibiotic selection reduce length of hospital stay of patients with community-acquired penumonia: link between quality of care and resource utilization. Arch Intern Med 2002; 162: 682–8 Leroy O, Santre C, Beuscart C. A 5-year study of severe community-acquired pneumonia with emphasis on prognosis in patients admitted to an ICU. Intensive Care Med 1995; 21: 24–31 Niederman M, Mandell L, Anzueto A, et al. Guidelines for the management of adults with community-acquired pneumonia: diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001; 163(7): 1730–54 Fang GD, Fine M, Orloff J, et al. New and emerging etiologies for community acquired pneumonia with implications for therapy. Medicine 1990; 69: 307–16 Bochud P-V, Moser F, Erard P, et al. Community-acquired pneumonia: a prospective outpatient study. Medicine 2001; 80: 75–87 Falguera M, Sacristan O, Nogues A, et al. Nonsevere community-acquired pneumonia: correlation between cause and severity or comorbidity. Arch Intern Med 2001; 161: 1866–72 Hansman D, Glasgow H, Surt J, et al. Increased resistance to penicillin of pneumococci isolated from man. N Engl J Med 1971; 284: 175–7 Hansman D, Bullen MM. A resistant pneumococcus. Lancet 1967; II: 264–5 Heffelfinger JD, Dowell SF, Jorgensen JH, et al. Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the drug-resistant Streptococcus pneumoniae therapeutic working group. Arch Intern Med 2000; 160: 1399–408 Thornsberry C, Sahm DF, Kelly LJ, et al. Regional trends in antimicrobial resistance among clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States: results from the TRUST Surveillance Program, 1999–2000. Clin Infect Dis 2002; 34Suppl. 1: S4–S16 Song JH, Lee NY, Ichiyama S, et al. Spread of drug resistant Streptococcus pneumoniae in Asia countries: Asian Network for Surveillance of Resistant Pathogens (ANSORP) study. Clin Infect Dis 1999; 28: 1206–11 Appelbaum PC. Antimicrobial resistance in Streptococcus pneumoniae: an overview. Clin Infect Dis 1992; 15: 77–83 Munoz R, Coffey TJ, Daniels M, et al. Intercontinental spread of a multiresistant clone of serotype 23F Streptococcus pneumoniae. J Infect Dis 1991; 164: 302–6 Soares S, Kristinsson KG, Musser JM, et al. Evidence for the introduction of a multiresistant clone of 6B Streptococcus pneumoniae from Spain to Iceland in the late 1980s. J Infect Dis 1993; 168: 158–63 Jabes D, Nachman S, Tomasz A. A penicillin-binding protein families: evidence for clonal nature of penicillin resistance in clinical isolates of pneumococci. J Infect Dis 1989; 159: 16–25 Kalin M, Ortqvist A, Almela M, et al. Prospective study of prognostic factors in community-acquired bacteremic pneumococcal disease in 5 countries. J Infect Dis 2000; 182: 840–7 Nasrin D, Collignon PJ, Roberts L, et al. Effect of β lactam antibiotic use in children on pneumococcal resistance to penicillin: prospective cohort study. BMJ 2002; 324: 28–30 Bauer T, Ewig S, Marcos MA, et al. Streptococcus pneumoniae in community-acquired pneumonia: how important is drug resistance? Med Clin North Am 2001; 85: 1367–79 Shortridge VD, Doern GV, Bruggemann AB, et al. Prevalence of macrolide resistance mechanisms in Streptococcus pneumoniae isolates from a multicenter antibiotic resistance surveillance study conducted in the United States in 1994–1994. Clin Infect Dis 1999; 29: 1186–8 Lynch JP, Martinez FJ. Clinical relevance of macrolide-resistant Streptococcus pneumoniae for community-acquired pneumonia. Clin Infect Dis 2002; 34Suppl. 1: S27–46 Ho PL, Que TL, Tsang DNC, et al. Emergence of fluoroquinolone resistance among multiply resistant strains of Streptococcus pneumoniae in Hong Kong. Antimicrob Agents Chemother 1999; 43: 1310–3 Ailani RK, Agastya G, Ailani RK, et al. Doxycycline is a cost-effective therapy for hospitalized patients with community-acquired pneumonia. Arch Intern Med 1999; 159: 266–70 Cunha B. Doxycyline re-revisited. Arch Intern Med 1999; 159: 1006–7 Doern GV, Heilmann KP, Huynh HK, et al. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999–2000, including a comparison of resistance rates since 1994–1995. Antimicrob Agents Chemother 2001; 45: 1721–9 Chen DK, McGeer A, de Azavedo JC, et al. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N Engl J Med 1999; 341: 233–9 Davidson R, Cavalcanti R, Brunton JL, et al. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med 2002; 346: 747–50 Hooper DC. Mechanisms of action of antimicrobials: focus on fluoroquinolones. Clin Infect Dis 2001; 32Suppl. 1: S9–S15 Marrie TJ, Peeling RW, Fine MJ, et al. Ambulatory patients with community-acquired pneumonia: the frequency of atypical agents and clinical course. Am J Med 1996; 101: 508–15 Gupta SK, Sarosi GA. The role of atypical pathogens in community-acquired pneumonia. Med Clin North Am 2001; 85: 1349–65 Gleason PP. The emerging role of atypical pathogens in community-acquired pneumonia. Pharmacotherapy 2002; 22(1 Pt 2): 2S–11S Weingarten SR, Riedinger MS, Hobson P, et al. Evaluation of a pneumonia practice guideline in an interventional trial. Am J Respir Crit Care Med 1996; 153: 1110–5 Van den Brande P, Vondra V, Vogel F, et al. Sequential therapy with cefuroxime followed by cefuroxime axetil in community-acquired pneumonia. Chest 1997; 112(2): 406–15 Ramirez J, Srinath L, Ahkee S, et al. Early switch from intravenous to oral cephalosporins in the treatment of hospitalized patients with community-acquired pneumonia. Arch Intern Med 1995; 155(12): 1273–6 Hendrickson J, North D. Pharmacoeconomic benefit of antibiotic step-down therapy: converting patients from intravenous ceftriaxone to oral cefpodoxime proxetil. Ann Pharmacother 1995; 29: 561–5 Rhew D, Tu G, Ofman J, et al. Early switch and early discharge strategies in patients with community-acquired pneumonia: a meta-analysis. Arch Intern Med 2001; 161(5): 722–7 Andaya MRP, Raab TA. Is one day of in-hospital observation after switching from intravenous to oral antibiotic therapy in the treatment of community acquired pneumonia necessary. Infect Dis Clin Pract 2000; 9(9): 372–5 Rhew D, Hackner D, Henderson L, et al. The clinical benefit of in-hospital observation in ‘low-risk’ pneumonia patients after conversion from parenteral to oral antimicrobial therapy. Chest 1998; 113(1): 142–6 Dunn AS, Peterson KL, Schechter CB, et al. The utility of an in-hospital observation period after discontinuing intravenous antibiotics. Am J Med 1999; 106: 6–10 Fine MJ, Pratt IIM, Obrosky DS, et al. Relation between length of hospital stay and costs of care for patients with community-acquired pneumonia. Am J Med 2000; 109: 378–85 Halm E, Fine JM, Kapoor WN, et al. Instability on hospital discharge and the risk of adverse outcomes in patients with pneumonia. Arch Intern Med 2002; 162: 1278–84 Ramirez J, Vargas S, Ritter G, et al. Early switch from intravenous to oral antibiotics and early hospital discharge: a prospective observational study of 200 consecutive patients with community-acquired pneumonia. Arch Intern Med 1999; 159(20): 2449–54 Ramirez J, Bordon J. Early switch from intravenous to oral antibiotics in hospitalized patients with bacteremic community-acquired Streptococcus pneumoniae pneumonia. Arch Intern Med 2001; 161(6): 848–50 Plouffe J, Schwartz DB, Kolokathis A, et al. Clinical efficacy of intravenous followed by oral azithromycin monotherapy in hospitalized patients with community-acquired pneumonia. Antimicrob Agents Chemother 2000; 44: 1796–802 Vergis EN, Indorf A, File Jr TM, et al. Azithromycin vs cefuroxime plus erythromycin for empirical treatment of community-acquired pneumonia in hospitalized patients: a prospective, randomized, multicenter trial. Arch Intern Med 2000; 160: 1294–300 File Jr TM. Appropriate use of antimicrobials for drug-resistance pneumonia: focus on the significance of β-lactam-resistant Streptococcus pneumoniae. Clin Infect Dis 2002; 34Suppl. 1: S17–26 Waterer GW, Wunderink RG. Fatal pneumococcal pneumonia attributed to macrolide resistance and azithromycin monotherapy. Chest 2000; 118: 1839–40 Fogarty C, Goldschmidt R, Bush K. Bacteremic pneumonia due to multidrugresistant pneumococci in 3 patients treated unsuccessfully with azithromycin and successfully with levofloxacin. Clin Infect Dis 2000; 31: 613–5 Kelley MA, Weber DJ, Gilligan P, et al. Breakthrough pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin. Clin Infect Dis 2000; 31: 1008–11 Waterer G, Somes G, Wunderink R. Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch Intern Med 2001; 161(15): 1837–42 Castro-Guardiola A, Viejo-Rodriguez A, Soler-Simon S, et al. Efficacy and safety of oral and early-switch therapy for community-acquired pneumonia: a randomized controlled trial. Am J Med 2001; 111(5): 367–74 Cassiere H, Fein A. Duration and route of antibiotic therapy in community-acquired pneumonia: switch and step-down therapy. Semin Respir Infect 1998; 13(1): 36–42 Cunha B. Oral or intravenous-to-oral antibiotic switch therapy for treating patients with community-acquired pneumonia. Am J Med 2001; 111(5): 412–3 Krumpe P, Cohn S, Garreltes J, et al. Intravenous and oral mono- or combination-therapy in the treatment of severe infections: ciprofloxacin versus standard antibiotic therapy. Ciprofloxacin Study Group. J Antimicrob Chemother 1999; 43Suppl. A: 117–28 Nathwani D, Boyter A, Fegan P, et al. Switch therapy in community-acquired pneumonia [letter]. Arch Intern Med 1996; 156(11): 1235 Omidvari K, de Boisblanc BP, Karam G, et al. Early transition to oral antibiotic therapy for community-acquired pneumonia: duration of therapy, clinical outcomes, and cost analysis. Respir Med 1998; 92(8): 1032–9 Press R. The use of fluoroquinolones as antiinfective transition-therapy agents in community-acquired pneumonia. Pharmacotherapy 2001; 21(7 Pt 2): 100S–4S Ramirez J. Switch therapy with beta-lactam/beta-lactamase inhibitors in patients with community-acquired pneumonia. Ann Pharmacother 1998; 32(1): S22–6 Ramirez J. Managing antiinfective therapy of community-acquired pneumonia in the hospital setting: focus on switch therapy. Pharmacotherapy 2001; 21(7 Pt 2): 79S–82S Siegel R. Strategies for early discharge of the hospitalized patient with community-acquired pneumonia. Clin Chest Med 1999; 20(3): 599–605